Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 18;13(20):5222.
doi: 10.3390/cancers13205222.

FDG-PET/CT in Lymphoma: Where Do We Go Now?

Yassine Al Tabaa  1 , Clement Bailly  2   3 , Salim Kanoun  4   5
Affiliations

FDG-PET/CT in Lymphoma: Where Do We Go Now?

Yassine Al Tabaa et al. Cancers (Basel). .

Abstract

18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future.

Keywords: Deauville 5PS; FDG-PET; lymphomas.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
FDG-PET/CT criteria for staging and response assessment in lymphoma (aaIPI: age-adjusted International Prognostic Index; C2: after 2 cycles of chemotherapy; C4: after 4 cycles of chemotherapy; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; HL: Hodgkin lymphoma; SUVmax: maximum standard uptake value).
Figure 2
Figure 2
Receptors and metabolic pathways for molecular imaging applications in lymphoma.
See this image and copyright information in PMC

References

    1. Cheson B.D. Role of Functional Imaging in the Management of Lymphoma. J. Clin. Oncol. 2011;29:1844–1854. doi: 10.1200/JCO.2010.32.5225. - DOI - PubMed
    1. Barrington S.F., Mikhaeel N.G., Kostakoglu L., Meignan M., Hutchings M., Müeller S.P., Schwartz L.H., Zucca E., Fisher R.I., Trotman J., et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J. Clin. Oncol. 2014;32:3048–3058. doi: 10.1200/JCO.2013.53.5229. - DOI - PMC - PubMed
    1. Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., Lister T.A., Alliance, Australasian Leukaemia and Lymphoma Group. Eastern Cooperative Oncology Group. European Mantle Cell Lymphoma Consortium et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J. Clin. Oncol. 2014;32:3059–3068. doi: 10.1200/JCO.2013.54.8800. - DOI - PMC - PubMed
    1. El-Galaly T.C., d’Amore F., Mylam K.J., de Nully Brown P., Bøgsted M., Bukh A., Specht L., Loft A., Iyer V., Hjorthaug K., et al. Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography-Staged Treatment-Naive Patients with Hodgkin Lymphoma. J. Clin. Oncol. 2012;30:4508–4514. doi: 10.1200/JCO.2012.42.4036. - DOI - PubMed
    1. Khan A.B., Barrington S.F., Mikhaeel N.G., Hunt A.A., Cameron L., Morris T., Carr R. PET-CT Staging of DLBCL Accurately Identifies and Provides New Insight into the Clinical Significance of Bone Marrow Involvement. Blood. 2013;122:61–67. doi: 10.1182/blood-2012-12-473389. - DOI - PubMed

LinkOut - more resources